UAE withdraws some products of pharma firm

MoHAP instructed all pharmacies to stop dispensing these products and return them to the supplier


The UAE’s Ministry of Health and Prevention (MoHAP) has issued a decision withdrawing a number of pharmaceutical products manufactured by Julphar (Gulf Pharmaceutical Industries) after being found non-compliant with the approved specifications, a statement said.
The ministry's move comes after samples of the suspected medicines were tested at the Quality Control Laboratory in Dubai, especially as the manufacturer itself voluntarily recalled these drugs, it said.
MoHAP instructed all pharmacies to stop dispensing these products and return them to the supplier, urging all health care practitioners and community members to refrain from using such products if they already in their possession.
The ministry listed the medicines voluntarily recalled as Julmentin 375mg used for treating bacterial infections and lungs, ears and sinuses infections; Mucolyte syrup, which is prescribed for mucous secretions; Butalin 2 and 4 mg tablet for bronchospasm, asthma and pulmonary embolism; and Lipigard 10mg tablet prescribed for treating cholesterol; Scopinal syrup used for colon disorders; Supraproct - s prescribed for haemorrhoids and rashes, and Gupisone 20 mg tablet which is used for allergies.
“The manufacturer has already been contacted and instructed to withdraw all batches of Profenal, which is analgesics, anti-inflammatories and antipyretics in children, due to non-conformity with the approved specifications in terms of the amount of the active substance, in addition to the existence of insoluble deposits on the top of the product's bottle wall that does not dissolve by shaking,” the ministry clarified.
The ministry stated that the decision to voluntarily withdraw and suspend some pharmaceutical products was no more than a precautionary measure to ensure the health and safety of patients. It also came as part of periodic tests carried out on random products that are examined at the ministry’s national reference laboratory to support the drug system in the country and monitor the quality of medicines being used, it said.
“We are closely following up on the withdrawal process and constantly coordinating with various international, regional and local pharmaceutical authorities and companies to keep abreast of any developments related to drug warnings,” the ministry said, affirming that the health and safety of the public is a top priority. -TradeArabia News Service

Copyright 2021 Al Hilal Publishing and Marketing Group Provided by SyndiGate Media Inc. (

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

More From Commercial